About Spasticity

Spasticity severely affects an estimated 12 million people worldwide, most specifically affecting those with neurological conditions. Nearly half a million people with cerebral palsy have some degree of spasticity, and about 320,000 people with MS experience severe spasticity.

 

Spasticity can vary in its severity. Mildly, it may be just slight muscle stiffness and spasms that are irregular. In severe cases, it can mean permanent contracture and pain that severely affects the ability to function normally.

 

Spasticity is associated with involuntary muscle spasms, sustained muscle contractions, and exaggerated deep tendon reflexes that can make simple movements and posture difficult and uncontrollable.

 

What Causes Spasticity

Various neurological conditions are associated with spasticities such as cerebral palsy, brain injury and trauma, stroke, multiple sclerosis, and spinal cord injury.

 

Any injury or disease that affects the brain’s ability to communicate to the muscles can cause spasticity. Spastic muscles are receiving improper nerve signals. Muscles become tense, spasms occur, contractions become prolonged, and rapid and repetitive jerky motions happen, and in spastic muscles, the brain is unable to properly attenuate the body.

 

Normal Treatments for Spasticity

The brain is able to control muscles via a constant flow of communicatory signals and messages involved with the nervous system. Injuries to the head and brain and various medical conditions can change the way the brain and body communicate.

 

In extreme cases, some doctors may suggest to patients with some types of surgeries or injections that essentially damage or affect nerves in some way that prevents them from becoming spastic. However, these types of treatments are considered risky and dangerous at best and can cause permanent nerve damage. There is a level of concern in the medical community about the widespread use of spasticity drugs that should be noted. Several studies indicate that there isn’t sufficient evidence for the safe prescription or recommendation of these drugs.

 

One of the leading pharmaceuticals used for treating spasticity in MS and CP is Baclofen, which is administered orally as well as intrathecally by the use of an implanted pump that continuously administers the drug. Orally, the drug can cause fatigue and impair cognitive functioning, which can actually reduce the effectiveness of rehabilitation therapy for patients.

 

When administered intrathecally, the drug’s complications become much worse, and can even be life-threatening. Studies suggest that patients can quickly develop tolerance to the drug leading to a dependency of higher toxic doses in order to achieve relief from spasm. When patients stop using the drug, they can experience what is referred to as intrathecal baclofen withdrawal syndrome, which can manifest as autonomic dysreflexia or even malignant hyperthermia.

 

Some clinicians may prescribe to patients with spasticity various types of muscle relaxers. Most of these drugs are highly toxic to the body’s internal organs and can cause fatigue, dangerously low blood pressure, and depression. Some muscle relaxers, such as SOMA, are known to be highly addictive and habit forming.

 

How Medical Marijuana Can Help Spasticity

In a 2008 study on [cannabinoids] in the management of spasticity associated with MS, researchers reviewed available scientific literature on the topic and found a mounting body of evidence suggesting that cannabinoids have beneficial effects on the spasticity and pain.

 

Research suggests that inflammation of the central nervous system in MS patients is mediated via the endocannabinoid [receptors]. [Phytocannabinoids] derived from marijuana have the ability to agonize the [endocannabinoid system], directly improving symptoms of inflammation, pain, and spasticity, as well as the quality of life of patients.

 

The authors of the aforementioned literary review conclude their study by stating that the emerging literature on the effects of cannabinoids could lead to the development of promising models for the therapy and management of disabling symptoms of the disease. This is important because current treatments of MS and CP are only partially effective and have risks of adverse effects not easily tolerated by patients.

 

Marijuana will affect individuals uniquely according to various factors including strain, administration method, and dosage. Consult with a physician and medical marijuana professional about using cannabis. Find linked below strains of medical marijuana that have been reported by others to relieve spastic muscles and associated painful conditions.

 

·   [[Alien Hallucination]]

·   [[Blue Magic]]

·   [[Caramella]]

·   [[Devil Fruit]]

·   [[Dream Beaver]]

·   [[Government Mule]]

·   [[Santa Sativa]]

·   [[Sour Spyder]]

·   [[Sweet Berry]]

·   [[Alpha Blue]]

·   [[Arctic Blue]]

·   [[Bay 11]]

·   [[Blackberry Haze]]

·   [[Blue Mystic]]

·   [[Blue Wonder]]

·   [[Blue Wreck]]

·   [[Blue Cheesecake]]

·   [[Bubbleberry C3PO]]

·   [[Crimea Blue]]

 

Sources:

AANS (2017) Spasticity. Web

Chou, Roger MD (2017) Journal of Pain and Symptom Management. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review

Rabchevsky, Alexander G. (2011) Neurotherapeutics. Latest Approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury

Malfitano, Anna Maria (2008) Neuropsychiatric Disease and Treatment. Cannabinoids in the management of spasticity associated with multiple sclerosis

Top Strains That May Help With Spasticity

Hybrid
 
Hybrid